Philip Ferrone, MD, to join Apellis Pharmaceuticals as Chief Medical Retina Advisor


Ferrone’s role will be effective as of March 18, 2024.

(Image credit: AdobeStock/Katsiaryna)

(Image credit: AdobeStock/Katsiaryna)

Philip Ferrone, MD, is set to join Apellis Pharmaceuticals Inc. as the company’s Chief Medical Retina Advisor. His title and position will be effective on March 18, 2024.

Ferrone is a retina specialist who serves as the director of clinical research at Vitreoretinal Consultants in New York and will continue in the role following his appointment at Apellis. In addition to his current work, Ferrone previously served as the president of the American Society of Retina Specialists (ASRS) and has been a part of the board of directors for 18 years. He is also a past president of The Foundation of the ASRS, which aims to raise patient awareness and education about retina health.1

In the news release1, Caroline Baumal, MD, Chief Medical Officer, Apellis, shared how “Phil is globally renowned for his leadership in retina, including as a past president of the American Society of Retina Specialists (ASRS), so we are delighted to welcome him to the Apellis team. Phil has extensive expertise in retina research and patient care, which will be invaluable as we continue to bring SYFOVRE to patients with GA and advance our retina pipeline.”

His direct work with the company’s pegcetacoplan injection (SYFOVRE) as treatment for geographic atrophy (GA) lends to his work in this role. On the subject of this new role, Ferrone shared his thought in a press release1, saying, “It is an honor to join Apellis in its mission to deliver life-changing treatments for patients living with serious diseases. I was an early adopter of SYFOVRE and have realized first-hand how impactful this treatment is for GA patients. I look forward to working closely with Caroline and this tremendously talented team to advance care for patients with this devastating disease.”

1. Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor. Apellis Pharmaceuticals, Inc. Published March 11, 2024. Accessed March 11, 2024.
Related Videos
TENAYA, LUCERNE year 2 data reveals promising results for faricimab
How to diagnose geographic atrophy earlier
World Sight Day 2022: Eye care professionals share what global vision means to them
Samsara Vision update: Concerto trial recruiting patients with late-stage AMD
Understanding fluid dynamics in wet macular degeneration
YOSEMITE, RHINE treat-and-extend data show favorable results for faricimab for the treatment of DME
What are you most excited about in the field of retina? Tunde Peto, MD, PhD weighs in
Leveraging noninvasive ophthalmic imaging for patients with Alzheimer disease and analyzing UK Biobank data
EURETINA 2022: Leadership discusses what to expect, outlines Women in Retina program
DAVIO trial update: 12-month safety results indicate no serious adverse events, reduced treatment burden
© 2024 MJH Life Sciences

All rights reserved.